Treatment of anemia and neutropenia in patients with chronic hepatitis C infection treated with peginterferon-ribavirin based regimens with or without protease inhibitors: a review of the clinical evidence

CADTH
Record ID 32012000655
English
Authors' recomendations: At present, there is no clear evidence that would suggest an advantage of one intervention (pharmacological intervention versus dose reduction) over another as a strategy for managing neutropenia in patients with chronic hepatitis C infection treated with PR. The evidence supporting the use of EPO versus ribavirin dose reduction in patients treated with PR who experience anemia is limited to small, underpowered studies. There is currently no evidence comparing pharmacological intervention with dose reduction in patients treated with protease inhibitor-PR regimens who experience anemia or neutropenia.
Details
Project Status: Completed
Year Published: 2012
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Hepatitis C, Chronic
  • Ribavirin
  • Interferon-alpha
  • Polyethylene Glycols
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: publications@cadth.ca
Contact Email: publications@cadth.ca
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.